Deborah A. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deborah A. Thomas has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Cortes
University of Alabama at Birmingham
21 shared publications - Hagop M. Kantarjian
Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA
13 shared publications Hagop Kantarjian
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
11 shared publicationsStefan Faderl
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
11 shared publications- Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center, Houston, TX
10 shared publications Hagop M. Kantarjian
From The University of Texas M. D. Anderson Cancer Center, Houston, TX
9 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7038
Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL).
7038 Background: Reports on the prognostic impact of cytogenetics in adult ALL have been inconsistent. While some studies report that low hypodiploidy (Ho) and complex karyotype (Cx) are adverse prognostic factors, more recent studies in patients (pts) receiving pediatric-inspired regimens have failed to confirm these findings. Methods: Between 2000 and 2015, 442 pts with Philadelphia negative (Ph-) ALL with pre-treatment cytogenetics were identified. 330 (75%) pts were treated with hyper-CVAD-based regimens, 98 (22%) with augmented-BFM. Cx was defined as ≥ 5 chromosomal (ch) abnormalities (excluding established translocations) given that there was no difference in survival between pts with 3-4 ch abnormalities and pts in the diploid (Dp) group (p= 0.51). Based on the choromosome number, pts were categorized as low hypodiploidy (Ho; 30-39 ch)/near triploidy (Tr; 60-78 ch) (analyzed together), high hyperdiploidy (HeH; 51-65 ch), and tetraploidy (Tt; ≥ 80 ch). Results: Median age was 40 years (13-86). 191 pts (43%) were Dp, 32 (7%) were Cx, 29 (6%) were Ho-Tr, 25 (5%) were HeH, 6 (1%) were Tt, and 28 (5%) pts had MLL rearrangement (MLL). Baseline characteristics were mostly similar among the groups. However, pts with Ho-Tr and Tt were significantly older than Dp pts (median age 62 and 68 vs. 39; p = 0.0001 and p = 0.0003, respectively), and pts with Ho-Tr had a lower platelet count than Dp pts (median platelets 25 vs. 45, p = 0.0008). 5-year OS rates are listed in the Table. Pts with MLL, Ho-Tr and Cx had significantly worse OS than did pts with Dp; in contrast, there was a trend towards longer OS for HeH pts. In a multivariate analysis, Cx was the only cytogenetic group predictive for survival and was the strongest predictor when compared to Dp with a HR of 2.8 (95% CI 1.6-4.7, p < 0.01). Other independent factors identified included age, WBC, albumin and performance status. OS among all cytogenetic groups was similar whether pts were treated with hyper-CVAD or augmented-BFM. Conclusions: In this cohort of adult Ph- ALL pts receiving two different types of treatment, complex karyotype was the only cytogenetic risk group independently prognostic for OS.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7038
Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL).
7038 Background: Reports on the prognostic impact of cytogenetics in adult ALL have been inconsistent. While some studies report that low hypodiploidy (Ho) and complex karyotype (Cx) are adverse prognostic factors, more recent studies in patients (pts) receiving pediatric-inspired regimens have failed to confirm these findings. Methods: Between 2000 and 2015, 442 pts with Philadelphia negative (Ph-) ALL with pre-treatment cytogenetics were identified. 330 (75%) pts were treated with hyper-CVAD-based regimens, 98 (22%) with augmented-BFM. Cx was defined as ≥ 5 chromosomal (ch) abnormalities (excluding established translocations) given that there was no difference in survival between pts with 3-4 ch abnormalities and pts in the diploid (Dp) group (p= 0.51). Based on the choromosome number, pts were categorized as low hypodiploidy (Ho; 30-39 ch)/near triploidy (Tr; 60-78 ch) (analyzed together), high hyperdiploidy (HeH; 51-65 ch), and tetraploidy (Tt; ≥ 80 ch). Results: Median age was 40 years (13-86). 191 pts (43%) were Dp, 32 (7%) were Cx, 29 (6%) were Ho-Tr, 25 (5%) were HeH, 6 (1%) were Tt, and 28 (5%) pts had MLL rearrangement (MLL). Baseline characteristics were mostly similar among the groups. However, pts with Ho-Tr and Tt were significantly older than Dp pts (median age 62 and 68 vs. 39; p = 0.0001 and p = 0.0003, respectively), and pts with Ho-Tr had a lower platelet count than Dp pts (median platelets 25 vs. 45, p = 0.0008). 5-year OS rates are listed in the Table. Pts with MLL, Ho-Tr and Cx had significantly worse OS than did pts with Dp; in contrast, there was a trend towards longer OS for HeH pts. In a multivariate analysis, Cx was the only cytogenetic group predictive for survival and was the strongest predictor when compared to Dp with a HR of 2.8 (95% CI 1.6-4.7, p < 0.01). Other independent factors identified included age, WBC, albumin and performance status. OS among all cytogenetic groups was similar whether pts were treated with hyper-CVAD or augmented-BFM. Conclusions: In this cohort of adult Ph- ALL pts receiving two different types of treatment, complex karyotype was the only cytogenetic risk group independently prognostic for OS.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7042
Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).
7042 Background: Chemoimmunotherapy is standard of care for patients (pts) with CD20+ ALL. Ofatumumab targets a unique small-loop epitope on CD20 and is more potent in vitro than rituximab. The combination of ofatumumab with hyper-CVAD may improve outcomes in ALL. Methods: 53 pts with Ph- CD20+ ALL, newly diagnosed (n = 49) or previously treated with 1 course of therapy (n = 4, 3 of whom were in CR at enrollment), received 8 cycles (cy) of hyper-CVAD (cy 1, 3, 5, 7) alternating with methotrexate (MTX) and cytarabine (cy 2, 4, 6, 8); ofatumumab was given during cy 1-4. Pts then received POMP maintenance for approximately 30 months (mos), interrupted by intensification with MTX/pegylated asparaginase in mos 6 and 18 and hyper-CVAD plus ofatumumab in mos 7 and 19. Results: Median age was 41 years (range: 18–71); median WBC was 4.6 x 109/L (range: 1-201 x 109/L). 19 pts (36%) had diploid karyotype. 32 pts (60%) had CD20 expression > 20%, 5 (9%) 10-20 % and 13 (25%) 1-10%. Of 50 pts evaluable for response, 49 (98%) achieved complete remission (CR) after 1 cycle; 1 pt died of sepsis during cycle 1. 48/52 pts (92%) became negative for minimal residual disease (MRD) as assessed by multicolor flow cytometry; of them 34 (67%) at CR. Median time to MRD negativity was 0.7 mos (range: 0.4-7.8). Median number of cy given was 7 (range: 1-8). Median times to neutrophil and platelet recovery after cycle 1 were 18 and 21 days, respectively. 67% of pts had febrile neutropenia during induction and 89% during consolidation. Grade ≥ 3 toxicity included high AST/ALT in 13 pts (32%), hyperbilirubinemia in 7 (17%), neuropathy in 3 (7%) and infusion reaction in 3 (7%). With a median follow-up of 16 mos (range: 1-53), 44 pts (83%) are alive: 41 in CR, 16 of whom are receiving POMP maintenance and 5 have completed all treatment. 6 pts received an allogeneic stem cell transplant after a median of 5 mos from treatment start (range: 4-8). 9 pts have died: 6 of relapse, 2 of sepsis and 1 of intracranial hemorrhage. The 2-year CR duration and overall survival rates were 74% and 83%, respectively. Conclusions: The combination of ofatumumab with hyper-CVAD is safe and highly effective in pts with CD20+ Ph- ALL. Clinical trial information: NCT01363128.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7042
Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).
7042 Background: Chemoimmunotherapy is standard of care for patients (pts) with CD20+ ALL. Ofatumumab targets a unique small-loop epitope on CD20 and is more potent in vitro than rituximab. The combination of ofatumumab with hyper-CVAD may improve outcomes in ALL. Methods: 53 pts with Ph- CD20+ ALL, newly diagnosed (n = 49) or previously treated with 1 course of therapy (n = 4, 3 of whom were in CR at enrollment), received 8 cycles (cy) of hyper-CVAD (cy 1, 3, 5, 7) alternating with methotrexate (MTX) and cytarabine (cy 2, 4, 6, 8); ofatumumab was given during cy 1-4. Pts then received POMP maintenance for approximately 30 months (mos), interrupted by intensification with MTX/pegylated asparaginase in mos 6 and 18 and hyper-CVAD plus ofatumumab in mos 7 and 19. Results: Median age was 41 years (range: 18–71); median WBC was 4.6 x 109/L (range: 1-201 x 109/L). 19 pts (36%) had diploid karyotype. 32 pts (60%) had CD20 expression > 20%, 5 (9%) 10-20 % and 13 (25%) 1-10%. Of 50 pts evaluable for response, 49 (98%) achieved complete remission (CR) after 1 cycle; 1 pt died of sepsis during cycle 1. 48/52 pts (92%) became negative for minimal residual disease (MRD) as assessed by multicolor flow cytometry; of them 34 (67%) at CR. Median time to MRD negativity was 0.7 mos (range: 0.4-7.8). Median number of cy given was 7 (range: 1-8). Median times to neutrophil and platelet recovery after cycle 1 were 18 and 21 days, respectively. 67% of pts had febrile neutropenia during induction and 89% during consolidation. Grade ≥ 3 toxicity included high AST/ALT in 13 pts (32%), hyperbilirubinemia in 7 (17%), neuropathy in 3 (7%) and infusion reaction in 3 (7%). With a median follow-up of 16 mos (range: 1-53), 44 pts (83%) are alive: 41 in CR, 16 of whom are receiving POMP maintenance and 5 have completed all treatment. 6 pts received an allogeneic stem cell transplant after a median of 5 mos from treatment start (range: 4-8). 9 pts have died: 6 of relapse, 2 of sepsis and 1 of intracranial hemorrhage. The 2-year CR duration and overall survival rates were 74% and 83%, respectively. Conclusions: The combination of ofatumumab with hyper-CVAD is safe and highly effective in pts with CD20+ Ph- ALL. Clinical trial information: NCT01363128.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7035
Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
7035 Background: The prognostic impact of D14 BM blast percentage in the context of minimal residual disease (MRD) status at complete response (CR) in pts with ALL undergoing induction chemotherapy has not been established. Methods: We evaluated the prognostic significance of D14 BM blast percentage in adults with previously untreated Ph- B-ALL or T-ALL undergoing induction chemotherapy with Augmented BFM or hyper-CVAD. All pts underwent BM examination on D14 ± 2 days. The D14 BM blast cutoff best predicting for overall survival (OS) was identified by comparing hazard ratios (HR) of various cutoffs by log-rank test. Pts with a blast-free aplastic BM were included in the < 10% group, as these groups had similar outcomes. The impact of MRD at CR was assessed using flow cytometry with a sensitivity of ≤ 0.01%. Results: Between 5/2000 and 9/2015, 389 pts were evaluable for response and BM assessment. Median duration of survivor follow-up was 28 months. Median percentage of D14 BM blasts was 2% (range: 0-97%). The optimal D14 BM blast cutoff predicting for OS was < 30% vs. ≥ 30%, which was used to stratify pts into 3 groups based on D14 BM blast percentage ( < 10% vs. 10%-29% vs. ≥ 30%). On D14 BM examination, 319 pts (82%) had < 10% blasts, 31 (8%) had 10-29% blasts, and 39 (10%) had ≥ 30% blasts. The CR/CRp rates for these 3 groups were 99.7%, 87% and 79%, and the rates of MRD negativity were 75%, 27% and 11%, respectively (P < 0.001 for both). Median event-free survival (EFS) was 49, 33 and 9 months; and median OS was 88, 37 and 21 months, respectively (P < 0.001 for both). By multivariate analysis, WBC, platelets, cytogenetics and MRD status at CR were independently associated with EFS, with a trend for worse EFS in pts with higher D14 BM blasts (HR 1.39 [0.98-1.98]; P = 0.07). Age, WBC, platelets, cytogenetics, MRD status at CR, and D14 BM blast risk group were all independently associated with OS (HR 1.43 [1.02-1.99] for D14 blast groups; P = 0.04). Conclusions: A high percentage of residual blasts on D14 BM in adult pts with Ph- ALL is highly predictive for inferior EFS and OS. Morphologic evaluation of D14 BM has prognostic value even when MRD information is taken into consideration.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7035
Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
7035 Background: The prognostic impact of D14 BM blast percentage in the context of minimal residual disease (MRD) status at complete response (CR) in pts with ALL undergoing induction chemotherapy has not been established. Methods: We evaluated the prognostic significance of D14 BM blast percentage in adults with previously untreated Ph- B-ALL or T-ALL undergoing induction chemotherapy with Augmented BFM or hyper-CVAD. All pts underwent BM examination on D14 ± 2 days. The D14 BM blast cutoff best predicting for overall survival (OS) was identified by comparing hazard ratios (HR) of various cutoffs by log-rank test. Pts with a blast-free aplastic BM were included in the < 10% group, as these groups had similar outcomes. The impact of MRD at CR was assessed using flow cytometry with a sensitivity of ≤ 0.01%. Results: Between 5/2000 and 9/2015, 389 pts were evaluable for response and BM assessment. Median duration of survivor follow-up was 28 months. Median percentage of D14 BM blasts was 2% (range: 0-97%). The optimal D14 BM blast cutoff predicting for OS was < 30% vs. ≥ 30%, which was used to stratify pts into 3 groups based on D14 BM blast percentage ( < 10% vs. 10%-29% vs. ≥ 30%). On D14 BM examination, 319 pts (82%) had < 10% blasts, 31 (8%) had 10-29% blasts, and 39 (10%) had ≥ 30% blasts. The CR/CRp rates for these 3 groups were 99.7%, 87% and 79%, and the rates of MRD negativity were 75%, 27% and 11%, respectively (P < 0.001 for both). Median event-free survival (EFS) was 49, 33 and 9 months; and median OS was 88, 37 and 21 months, respectively (P < 0.001 for both). By multivariate analysis, WBC, platelets, cytogenetics and MRD status at CR were independently associated with EFS, with a trend for worse EFS in pts with higher D14 BM blasts (HR 1.39 [0.98-1.98]; P = 0.07). Age, WBC, platelets, cytogenetics, MRD status at CR, and D14 BM blast risk group were all independently associated with OS (HR 1.43 [1.02-1.99] for D14 blast groups; P = 0.04). Conclusions: A high percentage of residual blasts on D14 BM in adult pts with Ph- ALL is highly predictive for inferior EFS and OS. Morphologic evaluation of D14 BM has prognostic value even when MRD information is taken into consideration.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7036
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7036 Background: Combination of cytotoxic chemotherapy with a tyrosine kinase inhibitor is effective in the treatment of Ph+ ALL. Ponatinib is a more potent BCR-ABL1 inhibitor than imatinib and dasatinib. The combination of chemotherapy with ponatinib might improve response rate and clinical outcome. Methods: In this phase II trial, 52 pts with newly diagnosed Ph+ ALL received 8 cycles (cy) of HCVAD alternating with high-dose MTX/Ara-C every 21 days. Ponatinib was given at 45 mg po daily for the first 14 days of cy 1 then continuously for the subsequent 7 cy at the dose of 30 mg then 15 mg once a CMR is achieved. Pts in CMR received maintenance with ponatinib and vincristine and prednisone monthly for 2 years followed by ponatinib. Results: To date 49 pts with untreated Ph+ ALL and 3 previously treated (2 with prior cy of chemotherapy before Ph+/BCR-ABL status was known not in CR, and 1 post HCVAD-dasatinib in CR) have a median follow-up of 31 months (1-50) (table 1). All pts were in CR after cy 1. 42 of the 46 (91%) with Ph+ metaphases achieved a CCyR after 1 cy; 2 had a minor cytogenetic response only and 2 had no cytogenetic analysis at CR, both of them achieved a CCyR after cy 2. To date, 50 (96%) have achieved a MMR, of whom 41 (79%) have achieved a CMR at a median of 10 weeks from initiation of treatment (2 -96). MRD status by flow cytometry is negative in 50 of the 51 (98%) at a median of 3 weeks (2-14). Median time to neutrophil and platelet recovery for cy 1 was 18 and 22 days, and 16 and 22 days for subsequent cy, respectively. 10 underwent allogeneic transplantation after a median of 4 cy (3-19). 2 had grade 5 vascular events (VE) with no underlying risk factors (1, MI; 1, NSTEMI). No further VE were reported with ponatinib dose optimization. The 3-y CR duration and OS rates were 79% and 82%, respectively. Conclusions: The combination of HCVAD with ponatinib is safe and effective in achieving molecular remissions in pts with Ph+ ALL. Clinical trial information: NCT01424982.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7036
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7036 Background: Combination of cytotoxic chemotherapy with a tyrosine kinase inhibitor is effective in the treatment of Ph+ ALL. Ponatinib is a more potent BCR-ABL1 inhibitor than imatinib and dasatinib. The combination of chemotherapy with ponatinib might improve response rate and clinical outcome. Methods: In this phase II trial, 52 pts with newly diagnosed Ph+ ALL received 8 cycles (cy) of HCVAD alternating with high-dose MTX/Ara-C every 21 days. Ponatinib was given at 45 mg po daily for the first 14 days of cy 1 then continuously for the subsequent 7 cy at the dose of 30 mg then 15 mg once a CMR is achieved. Pts in CMR received maintenance with ponatinib and vincristine and prednisone monthly for 2 years followed by ponatinib. Results: To date 49 pts with untreated Ph+ ALL and 3 previously treated (2 with prior cy of chemotherapy before Ph+/BCR-ABL status was known not in CR, and 1 post HCVAD-dasatinib in CR) have a median follow-up of 31 months (1-50) (table 1). All pts were in CR after cy 1. 42 of the 46 (91%) with Ph+ metaphases achieved a CCyR after 1 cy; 2 had a minor cytogenetic response only and 2 had no cytogenetic analysis at CR, both of them achieved a CCyR after cy 2. To date, 50 (96%) have achieved a MMR, of whom 41 (79%) have achieved a CMR at a median of 10 weeks from initiation of treatment (2 -96). MRD status by flow cytometry is negative in 50 of the 51 (98%) at a median of 3 weeks (2-14). Median time to neutrophil and platelet recovery for cy 1 was 18 and 22 days, and 16 and 22 days for subsequent cy, respectively. 10 underwent allogeneic transplantation after a median of 4 cy (3-19). 2 had grade 5 vascular events (VE) with no underlying risk factors (1, MI; 1, NSTEMI). No further VE were reported with ponatinib dose optimization. The 3-y CR duration and OS rates were 79% and 82%, respectively. Conclusions: The combination of HCVAD with ponatinib is safe and effective in achieving molecular remissions in pts with Ph+ ALL. Clinical trial information: NCT01424982.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7025
Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7025 Background: Combination of chemotherapy and tyrosine kinase inhibitor is standard of care in Ph+ ALL. The combination of HCVAD plus ponatinib induced a 3-y survival rate of 80%. The clinical efficacy of this combination has not been compared to that of HCVAD plus dasatinib. Methods: Response and survival for 109 pts with newly diagnosed Ph+ ALL enrolled in two consecutive prospective phase 2 clinical trials of frontline HCVAD with either ponatinib (n = 47; NCT01424982) or dasatinib (n = 62; NCT00390793) were analyzed. Logistic regression after multiple imputations for missing variables was used for propensity score (PS) calculation from baseline pt characteristics. PS analysis with 1:1 matching was performed with the nearest matching method with a caliper of 0.20. Results: PS matching identified 42 pts in each cohort (table 1). The median follow-up for pts treated with HCVAD and ponatinib and HCVAD and dasatinib was 31 and 67 months, respectively. Complete response (CR) rate and minimal residual disease (MRD) status at CR did not differ [CR, 100% vs. 95%, respectively (p = .359); MRD, 74% vs. 56%, respectively (p = .091)]. 1-y and 3-y EFS and OS were superior with HCVAD + ponatinib compared to HCVAD + dasatinib [1-y and 3-y EFS; 86% and 73% vs. 69% and 50%, respectively (p = .035): 1-y and 3-y OS; 89% and 83% vs. 74% and 60%, respectively (p = .041)]. Conclusions: The clinical outcome of HCVAD + ponatinib appears superior to that of HCVAD + dasatinib. Prospective confirmation of these results is warranted.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7025
Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7025 Background: Combination of chemotherapy and tyrosine kinase inhibitor is standard of care in Ph+ ALL. The combination of HCVAD plus ponatinib induced a 3-y survival rate of 80%. The clinical efficacy of this combination has not been compared to that of HCVAD plus dasatinib. Methods: Response and survival for 109 pts with newly diagnosed Ph+ ALL enrolled in two consecutive prospective phase 2 clinical trials of frontline HCVAD with either ponatinib (n = 47; NCT01424982) or dasatinib (n = 62; NCT00390793) were analyzed. Logistic regression after multiple imputations for missing variables was used for propensity score (PS) calculation from baseline pt characteristics. PS analysis with 1:1 matching was performed with the nearest matching method with a caliper of 0.20. Results: PS matching identified 42 pts in each cohort (table 1). The median follow-up for pts treated with HCVAD and ponatinib and HCVAD and dasatinib was 31 and 67 months, respectively. Complete response (CR) rate and minimal residual disease (MRD) status at CR did not differ [CR, 100% vs. 95%, respectively (p = .359); MRD, 74% vs. 56%, respectively (p = .091)]. 1-y and 3-y EFS and OS were superior with HCVAD + ponatinib compared to HCVAD + dasatinib [1-y and 3-y EFS; 86% and 73% vs. 69% and 50%, respectively (p = .035): 1-y and 3-y OS; 89% and 83% vs. 74% and 60%, respectively (p = .041)]. Conclusions: The clinical outcome of HCVAD + ponatinib appears superior to that of HCVAD + dasatinib. Prospective confirmation of these results is warranted.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7034
Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7034 Background: Minimal residual disease (MRD) assessment can identify patients with ALL at increased risk for relapse and death. However, the impact of achieving CMR in Ph+ ALL remains undefined. Methods: Between 4/2001 and 12/2015, 202 adult patients with Ph+ ALL received frontline chemotherapy plus a tyrosine kinase inhibitor at our institution. Of these, 196 achieved CR and 122 had MRD assessments for BCR-ABL1 by RQ-PCR both at CR and at 3-month time points; 37 patients underwent stem cell transplant (SCT) and were excluded, leaving 85 patients evaluable for this analysis. Patients received hyperCVAD plus imatinib (n = 23), dasatinib (n = 39) or ponatinib (n = 23). Major molecular response (MMR) was defined as a BCR-ABL1/ABL1 ratio < 0.1% standardized to the international scale, and CMR was defined as the absence of a quantifiable BCR-ABL1 transcript. Results: Median duration of survivor follow-up was 30 months. Molecular response rates at CR and at 3 months and their respective 3-year OS and RFS rates are summarized in the Table. Overall, MRD status at 3 months had better discrimination for OS and RFS than did MRD status at CR. At CR, no difference in OS or RFS was observed between patients achieving CMR and those with lesser responses (P = 0.26 and P = 0.15, respectively). At 3 months, achievement of CMR was associated with longer median OS and RFS compared to those with lesser responses (127 vs. 38 months, P = 0.009; and 126 vs. 18 months, P = 0.007, respectively). Patients with CMR at 3 months also had superior OS and RFS compared to those who achieved MMR at the same time point (P = 0.04 and P = 0.05, respectively). Among the 51 patients who achieved CMR at 3 months, there was no impact of molecular response at CR on either OS or RFS (P = 0.79 and 0.48, respectively). Conclusions: Patients with Ph+ ALL who achieve CMR at 3 months have superior outcomes compared to those with lesser molecular responses.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 7034
Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
7034 Background: Minimal residual disease (MRD) assessment can identify patients with ALL at increased risk for relapse and death. However, the impact of achieving CMR in Ph+ ALL remains undefined. Methods: Between 4/2001 and 12/2015, 202 adult patients with Ph+ ALL received frontline chemotherapy plus a tyrosine kinase inhibitor at our institution. Of these, 196 achieved CR and 122 had MRD assessments for BCR-ABL1 by RQ-PCR both at CR and at 3-month time points; 37 patients underwent stem cell transplant (SCT) and were excluded, leaving 85 patients evaluable for this analysis. Patients received hyperCVAD plus imatinib (n = 23), dasatinib (n = 39) or ponatinib (n = 23). Major molecular response (MMR) was defined as a BCR-ABL1/ABL1 ratio < 0.1% standardized to the international scale, and CMR was defined as the absence of a quantifiable BCR-ABL1 transcript. Results: Median duration of survivor follow-up was 30 months. Molecular response rates at CR and at 3 months and their respective 3-year OS and RFS rates are summarized in the Table. Overall, MRD status at 3 months had better discrimination for OS and RFS than did MRD status at CR. At CR, no difference in OS or RFS was observed between patients achieving CMR and those with lesser responses (P = 0.26 and P = 0.15, respectively). At 3 months, achievement of CMR was associated with longer median OS and RFS compared to those with lesser responses (127 vs. 38 months, P = 0.009; and 126 vs. 18 months, P = 0.007, respectively). Patients with CMR at 3 months also had superior OS and RFS compared to those who achieved MMR at the same time point (P = 0.04 and P = 0.05, respectively). Among the 51 patients who achieved CMR at 3 months, there was no impact of molecular response at CR on either OS or RFS (P = 0.79 and 0.48, respectively). Conclusions: Patients with Ph+ ALL who achieve CMR at 3 months have superior outcomes compared to those with lesser molecular responses.
- 14 June 2015
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (12) , 2704-2714
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Purpose: Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Experimental Design: Twenty-four patients were treated; 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD. Results: The median age of patients was 25 years (range, 11–64) and median number of prior treatments was 2 (range, 1–7). Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day. Responses included complete remission (CR) in 6 patients (25%), CR without platelet recovery (CRp) in 1 (4%), and CR without recovery of counts (CRi) in 1 (4%), for an overall response rate of 33%. In addition, partial response (PR) was noted in 2 patients (8%). Seven of 11 patients treated in first salvage achieved CR/CRp (64%). The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond (P ≤ 0.001). A response was noted in 5 of 10 (50%) heavily pretreated T-ALL patients (median of 4 prior salvage regimens). Everolimus significantly inhibited phosphorylation of S6RP, but this did not correlate with response. No significant decreases in p4EBP1 and pAkt levels were noted. Responders had higher everolimus dose-adjusted area under the curve (P = 0.025) and lower clearance (P = 0.025) than nonresponders. Conclusions: The combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL, specifically T-ALL. Clin Cancer Res; 21(12); 2704–14. ©2015 AACR.
- 14 June 2015
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (12) , 2704-2714
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Purpose: Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Experimental Design: Twenty-four patients were treated; 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD. Results: The median age of patients was 25 years (range, 11–64) and median number of prior treatments was 2 (range, 1–7). Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day. Responses included complete remission (CR) in 6 patients (25%), CR without platelet recovery (CRp) in 1 (4%), and CR without recovery of counts (CRi) in 1 (4%), for an overall response rate of 33%. In addition, partial response (PR) was noted in 2 patients (8%). Seven of 11 patients treated in first salvage achieved CR/CRp (64%). The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond (P ≤ 0.001). A response was noted in 5 of 10 (50%) heavily pretreated T-ALL patients (median of 4 prior salvage regimens). Everolimus significantly inhibited phosphorylation of S6RP, but this did not correlate with response. No significant decreases in p4EBP1 and pAkt levels were noted. Responders had higher everolimus dose-adjusted area under the curve (P = 0.025) and lower clearance (P = 0.025) than nonresponders. Conclusions: The combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL, specifically T-ALL. Clin Cancer Res; 21(12); 2704–14. ©2015 AACR.
- 20 June 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (10) , 920-921
Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis
- 20 June 2013
- Published by Wiley in American Journal of Hematology
- Vol. 88 (10) , 920-921
Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis
- 1 September 2012
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (9) , 860-862
Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia
- 1 September 2012
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (9) , 860-862
Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia
- 31 December 2010
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 6 (1) , 58-66
Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?
Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, “B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL.” This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.
- 31 December 2010
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 6 (1) , 58-66
Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?
Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, “B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL.” This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.